Lorlatinib (PF-06463922) 99% Lorlatinib Lorlatinib manufacturer
Lorcaserin(856681-05-5)is an orally administered agent and a selective 5-HT2C receptor agonist for the treatment of obesity. It had been approved for marketing in US by FDA on 27 June in 2012. In clinical studies, lorcaserin has demonstrated efficacy in obese and overweight populations by promoting weight loss and improving metabolic parameters, and it is well tolerated.
CAS: | 1454846-35-5 |
MF: | C21H19FN6O2 |
MW:406.4129632 | 406.4129632 |
Appearance: | White powder |
Assay: | 99% |
Boiling point: | 675.0±55.0 °C(Predicted) |
desnity: | 1.42±0.1 g/cm3(Predicted) |
Uses: | Lorlatinib is a selective tyrosine kinase receptor inhibitor used in the therapy of selected cases of advanced non-small cell lung cancer. |
CAS NO:7647-15-6
CAS NO:420-37-1
CAS NO:13598-36-2
CAS NO:97416-84-7
CAS NO:15761-39-4
CAS NO:118-75-2
About|Contact|Cas|Product Name|Molecular|Country|Encyclopedia
Message|New Cas|MSDS|Service|Advertisement|CAS DataBase|Article Data|Manufacturers | Chemical Catalog
©2008 LookChem.com,License: ICP
NO.:Zhejiang16009103
complaints:service@lookchem.com Desktop View